Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen phase 3 placebo-controlled trial for prevention of COVID-19 in adults
IRCT20150303021315N24Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SpikoGen vaccine with Placebo (2 arms). Primary endpoints: Incidence of COVID-19 disease and Incidence of severe COVID-19 disease. Started Aug 2021; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150303021315N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N24.